SCHEMBL15524009

SCHEMBL15524009

C#CC[C@@H](NC(=O)O)[C@@H](O)c1cc(F)ccc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 3/20 0.40
CES1 P23141 3/20 0.40
PKM P14618 1/20 0.32
PSEN1 P49768 2/20 0.31
PSEN2 P49810 2/20 0.31
APH1B Q8WW43 2/20 0.31
NCSTN Q92542 2/20 0.31
APH1A Q96BI3 2/20 0.31
PSENEN Q9NZ42 2/20 0.31
MME P08473 1/20 0.31
ECE1 P42892 1/20 0.31
FFAR1 O14842 1/20 0.31
FFAR4 Q5NUL3 1/20 0.31
PSMB11 A5LHX3 1/20 0.31
PSMA7 O14818 1/20 0.31
PSMB1 P20618 1/20 0.31
PSMA1 P25786 1/20 0.31
PSMA2 P25787 1/20 0.31
PSMA3 P25788 1/20 0.31
PSMA4 P25789 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15524008 1.00 CES2 (0.40) CES2CES1PKMPSEN1PSEN2
SCHEMBL15524496 1.00 CES2 (0.40) CES2CES1PKMPSEN1PSEN2
SCHEMBL15524498 1.00 CES2 (0.40) CES2CES1PKMPSEN1PSEN2
SCHEMBL19712089 1.00 CES2 (0.40) CES2CES1PKMPSEN1PSEN2
SCHEMBL18760097 0.85
SCHEMBL17121659 0.82 CES2 (0.37) CES2CES1PSEN1PSEN2APH1B
SCHEMBL17921196 0.82 CES2 (0.37) CES2CES1PSEN1PSEN2APH1B
SCHEMBL12833411 0.82 TRPA1 (0.41) CES2CES1
SCHEMBL17380662 0.82 TRPA1 (0.41) CES2CES1
SCHEMBL12761888 0.82 TRPA1 (0.41) CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181262-B2 Crystalline forms of a dipeptidyl peptidase-IV inhibitors MERCK SHARP & DOHME CORP (US) 2015-11-10 US disclosed
US-20150099891-A1 NOVEL CRYSTALLINE FORMS OF A DIPEPTIDYL PEPTIDASE-IV INHIBITORS MERCK SHARP & DOHME LLC 2015-04-09 US disclosed
US-8895603-B2 Crystalline forms of a dipeptidyl peptidase-IV inhibitor MERCK SHARP & DOHME CORP. (US) 2014-11-25 US disclosed
US-20140080884-A1 NOVEL CRYSTALLINE FORMS OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR MERCK SHARP & DOHME LTD. (GB) 2014-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099891-A1 NOVEL CRYSTALLINE FORMS OF A DIPEPTIDYL PEPTIDASE-IV INHIBITORS DPP4, DPP3, DPP7 CES2 2242/4885CES1 684/4885PKM 2686/4885
US-20140080884-A1 NOVEL CRYSTALLINE FORMS OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR DPP4, DPP3, DPP7 CES2 2309/4885CES1 696/4885PKM 2742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.